A ferritin-based COVID-19 nanoparticle vaccine that elicits robust, durable, broad-spectrum neutralizing antisera in non-human primates

Payton A.-B. Weidenbacher, Mrinmoy Sanyal, Natalia Friedland, Shaogeng Tang, Prabhu S. Arunachalam, Mengyun Hu, Ozan S. Kumru, Mary Kate Morris, Jane Fontenot, Lisa Shirreff, Jonathan Do, Ya-Chen Cheng, Gayathri Vasudevan, Mark B. Feinberg, Francois J. Villinger, Carl Hanson, Sangeeta B. Joshi, David B. Volkin, Bali Pulendran and Peter S. Kim ()
Additional contact information
Payton A.-B. Weidenbacher: Stanford University
Mrinmoy Sanyal: Stanford University
Natalia Friedland: Stanford University
Shaogeng Tang: Stanford University
Prabhu S. Arunachalam: Stanford University School of Medicine
Mengyun Hu: Stanford University School of Medicine
Ozan S. Kumru: University of Kansas
Mary Kate Morris: California Department of Public Health
Jane Fontenot: University of Louisiana at Lafayette
Lisa Shirreff: University of Louisiana at Lafayette
Jonathan Do: Stanford University
Ya-Chen Cheng: Stanford University
Gayathri Vasudevan: IAVI
Mark B. Feinberg: IAVI
Francois J. Villinger: University of Louisiana at Lafayette
Carl Hanson: California Department of Public Health
Sangeeta B. Joshi: University of Kansas
David B. Volkin: University of Kansas
Bali Pulendran: Stanford University School of Medicine
Peter S. Kim: Stanford University

Nature Communications, 2023, vol. 14, issue 1, 1-13

Abstract: Abstract While the rapid development of COVID-19 vaccines has been a scientific triumph, the need remains for a globally available vaccine that provides longer-lasting immunity against present and future SARS-CoV-2 variants of concern (VOCs). Here, we describe DCFHP, a ferritin-based, protein-nanoparticle vaccine candidate that, when formulated with aluminum hydroxide as the sole adjuvant (DCFHP-alum), elicits potent and durable neutralizing antisera in non-human primates against known VOCs, including Omicron BQ.1, as well as against SARS-CoV-1. Following a booster ~one year after the initial immunization, DCFHP-alum elicits a robust anamnestic response. To enable global accessibility, we generated a cell line that can enable production of thousands of vaccine doses per liter of cell culture and show that DCFHP-alum maintains potency for at least 14 days at temperatures exceeding standard room temperature. DCFHP-alum has potential as a once-yearly (or less frequent) booster vaccine, and as a primary vaccine for pediatric use including in infants.

Date: 2023
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-023-37417-9 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:14:y:2023:i:1:d:10.1038_s41467-023-37417-9

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-023-37417-9

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().